Proxy Votes Now

Home › Funds › Fidelity › Fidelity Growth Company Fund

Fidelity Growth Company Fund (FDGRX) proxy voting record 2025-2026

Fund family: Fidelity · Filed by FIDELITY MT VERNON STREET TRUST (CIK 707823) · SEC series S000007119

Share classes and tickers: FDGRX (C000019448), FGCKX (C000064242)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 3,573 with, 205 against, 8 abstentions (not counted as with management); 14 items carried no recommendation. Shareholder proposals: 37 FOR, 177 AGAINST, 2 abstained, by the filing’s own vote-source field.

Compared with Fidelity as a whole

The same two figures as Fidelity’s manager page (1,165,189 ballot items across 406 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsFidelityItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)92.6%3,40594.1%974,562
Backed environmental and social shareholder proposals at US companies7.5%1066.8%11,096

Where this fund voted differently from most Fidelity funds

Each ballot item this fund voted is set against the votes of the other Fidelity funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most Fidelity funds on 74 items (2.0% of the 3,726 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost Fidelity fundsMgmtResult
Avis Budget Group, Inc.2026-05-20To elect as directors the six nominees named in the Company's Proxy Statement for a one-year term expiring in 2027 and until his or her successor is duly elected and qualified or until his or her earlier resignation or removal: Bernardo HeesAgainstFOR — 19 of 20 Fidelity fundsAgainstElected, 99.6% support
Avis Budget Group, Inc.2026-05-20To elect as directors the six nominees named in the Company's Proxy Statement for a one-year term expiring in 2027 and until his or her successor is duly elected and qualified or until his or her earlier resignation or removal: Jagdeep PahwaAgainstFOR — 19 of 20 Fidelity fundsAgainstElected, 99.6% support
Avis Budget Group, Inc.2026-05-20To elect as directors the six nominees named in the Company's Proxy Statement for a one-year term expiring in 2027 and until his or her successor is duly elected and qualified or until his or her earlier resignation or removal: Karthik SarmaAgainstFOR — 19 of 20 Fidelity fundsAgainstElected, 99.6% support
Avis Budget Group, Inc.2026-05-20Shareholder To vote, on an advisory basis, on a shareholder proposal to request that the Board of Directors take each step necessary so that each voting standard in our charter and bylaws that calls for a greater than simple majority vote be replaced by the applicable majority vote standard and to adjourn the aAgainstFOR — 18 of 20 Fidelity fundsForNot approved, 10.4% support
Illinois Tool Works Inc.2026-05-08Shareholder A non-binding stockholder proposal, if properly presented at the meeting, for Directors who fail to obtain a majority vote.ForAGAINST — 22 of 26 Fidelity fundsAgainstNot approved, 11.5% support
Cogent Communications Holdings, Inc.2026-05-01To elect eight directors to hold office until the next annual meeting of stockholders or until their respective successors have been elected or appointed: Deneen HowellAgainstFOR — 14 of 16 Fidelity fundsAgainstElected, 98.4% support
Cogent Communications Holdings, Inc.2026-05-01To elect eight directors to hold office until the next annual meeting of stockholders or until their respective successors have been elected or appointed: Marc MontagnerAgainstFOR — 14 of 16 Fidelity fundsAgainstElected, 97.4% support
Cogent Communications Holdings, Inc.2026-05-01To elect eight directors to hold office until the next annual meeting of stockholders or until their respective successors have been elected or appointed: Paul de SaAgainstFOR — 14 of 16 Fidelity fundsAgainstElected, 97.6% support
Nektar Therapeutics2026-06-04Election of Directors: Howard W. RobinAgainstFOR — 11 of 13 Fidelity fundsAgainstPassed (calculated), 72.6% support
Nektar Therapeutics2026-06-04To approve an amendment to our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 3,000,000 shares.AgainstFOR — 11 of 13 Fidelity fundsAgainstApproved, 72.9% support
Hyatt Hotels Corporation2026-05-20Election of Directors: Class II (to hold office until the 2029 annual meeting of stockholders): Richard C. TuttleForWITHHOLD — 15 of 19 Fidelity fundsForElected, 97.0% support
Ionis Pharmaceuticals, Inc.2026-06-04To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.AgainstFOR — 25 of 34 Fidelity fundsAgainstApproved, 77.0% support
The Hershey Company2026-05-05Election of Directors: Deirdre A. MahlanForAGAINST — 20 of 27 Fidelity fundsForPassed (calculated), 95.3% support
Prothena Corporation plc2026-05-14To elect, by separate resolutions, two directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2029, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Dennis J. SelkoeAgainstFOR — 12 of 15 Fidelity fundsAgainstElected, 72.8% support
Prothena Corporation plc2026-05-14To elect, by separate resolutions, two directors to hold office until no later than the Annual General Meeting of the Company's Shareholders in 2029, unless they resign, are removed from office, or are otherwise disqualified from serving as directors of the Company: Shane M. CookeAgainstFOR — 12 of 15 Fidelity fundsAgainstElected, 65.6% support
Block, Inc.2026-06-16TO ELECT FOUR CLASS II DIRECTORS TO SERVE UNTIL OUR 2029 ANNUAL MEETING OF STOCKHOLDERS AND UNTIL THEIR SUCCESSORS ARE DULY ELECTED AND QUALIFIED: AMY BROOKSForWITHHOLD — 17 of 23 Fidelity fundsForElected, 82.9% support
Cartesian Therapeutics, Inc.2026-06-12Election of Directors: Timothy A. Springer, Ph.D.WithholdFOR — 7 of 8 Fidelity fundsAgainstElected, 94.1% support
Sana Biotechnology, Inc.2026-06-04To elect three Class II directors to our Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The nominees for election are: Hans E. BishopWithholdFOR — 13 of 17 Fidelity fundsAgainst—
Paylocity Holding Corporation2025-12-04Approval of the Amended and Restated 2023 Equity Incentive Plan.AgainstFOR — 24 of 35 Fidelity fundsAgainstApproved, 96.1% support
CCC SA2026-01-15Shareholder Amend Statute Re: Company NameAgainstFOR — 9 of 11 Fidelity funds——
CCC SA2026-01-15Shareholder Amend Statute Re: Management BoardAgainstFOR — 9 of 11 Fidelity funds——
CCC SA2026-01-15Shareholder Authorize Share Repurchase Program; Approve Creation of Reserve Capital for Purposes of Share Repurchase ProgramForAGAINST — 9 of 11 Fidelity funds——
adidas AG2026-05-07Reelect Nassef Sawiris to the Supervisory BoardForAGAINST — 11 of 14 Fidelity fundsFor—
Akamai Technologies, Inc.2026-05-13Shareholder To vote upon a shareholder proposal requiring the Company to provide a report on political spending.ForAGAINST — 20 of 29 Fidelity fundsAgainstNot approved, 45.7% support
Akamai Technologies, Inc.2026-05-13To adjourn the Annual Meeting to a later date or dates, if necessary, to solicit additional proxies to establish a quorum or if there are insufficient votes to adopt any proposal (other than Proposal 8).AgainstFOR — 20 of 29 Fidelity fundsAgainstApproved, 56.7% support
Show all 74
Items 26 to 74.
CompanyMeetingItemThis fundMost Fidelity fundsMgmtResult
Akamai Technologies, Inc.2026-05-13To approve an amendment to our Second Amended and Restated 2013 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 8,000,000 shares.AgainstFOR — 20 of 29 Fidelity fundsAgainst—
Tectonic Therapeutic, Inc.2026-06-08Election of Directors: Timothy A. Springer, Ph.D.WithholdFOR — 12 of 16 Fidelity fundsAgainstPassed (calculated), 79.5% support
Nutanix, Inc.2025-12-12Approval of the amendment and restatement of our 2016 Equity Incentive Plan.AgainstFOR — 23 of 35 Fidelity fundsAgainstApproved, 76.5% support
Revolve Group, Inc.2026-06-05The election of directors: Michael MenteWithholdFOR — 13 of 18 Fidelity fundsAgainstElected, 93.3% support
ODDITY Tech Ltd.2025-11-13Reelect Shiran Holtzman-Erel as DirectorAgainstFOR — 8 of 10 Fidelity fundsAgainst—
Workday, Inc.2026-06-16To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement.ForAGAINST — 20 of 31 Fidelity fundsForApproved, 87.6% support
Roivant Sciences Ltd.2025-09-10To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Keith ManchesterWithholdFOR — 16 of 24 Fidelity fundsAgainstElected, 70.6% support
Roivant Sciences Ltd.2025-09-10To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Matthew GlineWithholdFOR — 16 of 24 Fidelity fundsAgainstElected, 73.6% support
Roivant Sciences Ltd.2025-09-10To elect the Board of Directors' three nominees for Class I Director to serve for a three-year term: Melissa EpperlyWithholdFOR — 16 of 24 Fidelity fundsAgainstElected, 73.5% support
Nuvation Bio Inc.2026-05-21Election of Directors: Robert BazemoreForWITHHOLD — 12 of 17 Fidelity fundsForElected, 84.0% support
Circle Internet Group, Inc.2026-05-14Election of Three Class I Directors: P. Sean NevilleAgainstFOR — 17 of 26 Fidelity fundsAgainstElected, 89.6% support
Globus Medical, Inc.2026-06-03Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders: Keith W. PfeilWithholdFOR — 18 of 28 Fidelity fundsAgainstElected, 91.3% support
The Trade Desk, Inc.2026-05-04The election of two Class I directors to hold office until our 2029 annual meeting of stockholders or until his or her successor is duly elected and qualified: Jeff T. GreenWithholdFOR — 19 of 30 Fidelity fundsAgainstPassed (calculated), 92.5% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Kenneth A. ClarkWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 96.1% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Mahkam ZanganehWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 98.5% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Manmeet S. SoniWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 98.4% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Robert W. DugganWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 98.3% support
Summit Therapeutics Inc.2026-06-10ELECTION OF DIRECTORS: Yu (Michelle) XiaWithholdFOR — 15 of 23 Fidelity fundsAgainstPassed (calculated), 98.3% support
SkinHealth Systems Inc.2026-06-10Election of Directors: Brian MillerWithholdFOR — 7 of 9 Fidelity fundsAgainstElected, 78.6% support
SkinHealth Systems Inc.2026-06-10Election of Directors: Doug SchillingerWithholdFOR — 7 of 9 Fidelity fundsAgainstElected, 84.9% support
SkinHealth Systems Inc.2026-06-10Election of Directors: E. Scott BeattieWithholdFOR — 7 of 9 Fidelity fundsAgainstElected, 84.8% support
Rivian Automotive, Inc.2026-06-22Election of Class II Directors to serve until the 2029 Annual Meeting of Stockholders: Aidan GomezWithholdFOR — 19 of 31 Fidelity fundsAgainstPassed (calculated), 92.4% support
Summit Therapeutics Inc.2026-06-10Approval, by a non-binding advisory vote, of the compensation of our named executive officers.ForAGAINST — 17 of 27 Fidelity fundsForPassed (calculated), 96.2% support
Atea Pharmaceuticals, Inc.2026-06-18Election of Class III Directors: Jerome Adams, MD, MPHWithholdFOR — 12 of 18 Fidelity fundsAgainstPassed (calculated), 56.4% support
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: Hongbo LuAgainstFOR — 14 of 22 Fidelity fundsAgainst—
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: William WaddillAgainstFOR — 14 of 22 Fidelity fundsAgainstPassed (calculated), 90.3% support
Southwest Airlines Co.2026-05-07Election of Directors: Sarah E. FeinbergAgainstFOR — 19 of 33 Fidelity fundsAgainstPassed (calculated), 94.8% support
Foghorn Therapeutics Inc.2026-06-24Elect Class III directors each for a three-year term: Douglas Cole, M.D.AgainstFOR — 7 of 10 Fidelity fundsAgainstElected, 76.2% support
Coinbase Global, Inc.2026-06-16Election of Directors: Fred WilsonWithholdFOR — 22 of 41 Fidelity fundsAgainstElected, 99.3% support
Coinbase Global, Inc.2026-06-16Election of Directors: Kelly A. KramerWithholdFOR — 22 of 41 Fidelity fundsAgainstElected, 99.4% support
Wayfair Inc.2026-05-21Election of Nine Directors: Andrea JungAbstainFOR — 19 of 34 Fidelity fundsAgainst—
Wayfair Inc.2026-05-21Election of Nine Directors: Michael E. SneedAbstainFOR — 19 of 34 Fidelity fundsAgainst—
Arrowhead Pharmaceuticals, Inc.2026-03-19Election of Directors: Michael S. PerryAgainstFOR — 13 of 22 Fidelity fundsAgainst—
Peloton Interactive, Inc.2025-12-09Election of Directors: Chris BruzzoForWITHHOLD — 16 of 28 Fidelity fundsForElected, 77.8% support
Rivian Automotive, Inc.2026-06-22Election of Class II Directors to serve until the 2029 Annual Meeting of Stockholders: Karen BooneWithholdFOR — 17 of 31 Fidelity fundsAgainstPassed (calculated), 81.4% support
Coinbase Global, Inc.2026-06-16Election of Directors: Frederick Ernest Ehrsam IIIWithholdFOR — 21 of 41 Fidelity fundsAgainstElected, 97.0% support
Coinbase Global, Inc.2026-06-16Election of Directors: Marc L. AndreessenWithholdFOR — 21 of 41 Fidelity fundsAgainstElected, 97.1% support
EquipmentShare.com Inc2026-06-04To elect to the Board of Directors seven nominees for one-year terms: Jennifer GiacomazzaWithholdFOR — 5 of 7 Fidelity fundsAgainstElected, 98.6% support
Atlassian Corporation2025-12-02Election of Directors: Richard P. WongForAGAINST — 16 of 31 Fidelity fundsForPassed (calculated), 94.8% support
Southwest Airlines Co.2026-05-07Election of Directors: Lisa M. AthertonAgainstFOR — 17 of 33 Fidelity fundsAgainstPassed (calculated), 91.0% support
Southwest Airlines Co.2026-05-07Election of Directors: Patricia A. WatsonAgainstFOR — 17 of 33 Fidelity fundsAgainstPassed (calculated), 92.3% support
Southwest Airlines Co.2026-05-07Election of Directors: Rakesh GangwalAgainstFOR — 17 of 33 Fidelity fundsAgainstPassed (calculated), 90.9% support
Nurix Therapeutics, Inc.2026-05-15Election of Class III Directors: Arthur T. Sands, M.D., Ph.D.WithholdFOR — 13 of 24 Fidelity fundsAgainstElected, 79.6% support
Nurix Therapeutics, Inc.2026-05-15Election of Class III Directors: Paul M. SilvaWithholdFOR — 13 of 24 Fidelity fundsAgainstElected, 74.2% support
SkinHealth Systems Inc.2026-06-10Approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers.AgainstFOR — 7 of 11 Fidelity fundsAgainstApproved, 82.6% support
Biomea Fusion, Inc.2026-06-10The election of Rainer (Ramses) Erdtmann and Eric Aguiar, M.D., as Class II Directors, to serve for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029: Rainer (Ramses) ErdtmannWithholdFOR — 4 of 7 Fidelity fundsAgainst—
CAMP4 Therapeutics Corporation2026-06-10Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Murray Stewart, DM FRCPAgainstFOR — 4 of 7 Fidelity fundsAgainst—
CAMP4 Therapeutics Corporation2026-06-10Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Richard Young, PhDAgainstFOR — 4 of 7 Fidelity fundsAgainst—
CAMP4 Therapeutics Corporation2026-06-10Election of the following nominees as our Class II Directors, each to serve for a three-year term until the 2029 annual meeting of our stockholders, and until his successor shall have been duly elected and qualified: Steven HoltzmanAgainstFOR — 4 of 7 Fidelity fundsAgainst—

Download all 74 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 82.7% of this fund’s 3,786 such votes could be given a sector; the other 654 (17.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Consumer Discretionary783658.3%
Technology753699.2%
Health Care675111.6%
Industrials314227.0%
Consumer Staples211157.1%
Finance1801810.0%
Energy7911.3%
Telecommunications6623.0%
Real Estate3812.6%
Basic Materials2800.0%
Utilities500.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2,4660
Audit-related3580
Say-on-Pay3070
Corporate Governance24478
Compensation1885
Capital Structure1180
Other Social Issues4845
Environment or Climate4343
Shareholder Rights and Defenses2315
Human Rights or Human Capital/workforce1616

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
NVIDIA CorporationJune 24, 2026$11.5B164
Apple Inc.February 24, 2026$8.4B121
Microsoft CorporationDecember 5, 2025$6.4B216
Meta Platforms, Inc.May 27, 2026$5.5B229
Amazon.com, Inc.May 20, 2026$4.9B174
Sandisk CorporationNovember 18, 2025$4.9B100
Alphabet Inc.June 5, 2026$3.3B2310
Eli Lilly and CompanyMay 4, 2026$2.7B102

Notable votes against management

MeetingCompanyProposalFundMgmt
June 24, 2026NVIDIA CorporationApproval of a non-binding stockholder proposal requesting the replacement of supermajority voting provisions in our charter and bylaws with a simple majority voting standard. Shareholder proposalForAgainst
June 24, 2026NVIDIA CorporationApproval of a non-binding stockholder proposal requesting a report on faith-based community resource groups. Shareholder proposalAgainstFor
February 24, 2026Apple Inc.A shareholder proposal entitled "China Entanglement Audit" Shareholder proposalAgainstFor
December 5, 2025Microsoft CorporationEuropean Security Program Censorship Risk Audit Shareholder proposalAgainstFor
December 5, 2025Microsoft CorporationReport on Risks of Censorship in Generative Artificial Intelligence Shareholder proposalAgainstFor
May 27, 2026Meta Platforms, Inc.A shareholder proposal regarding report on Al data usage oversight. Shareholder proposalAgainstFor
May 27, 2026Meta Platforms, Inc.A shareholder proposal regarding annual vote regarding executive pay. Shareholder proposalForAgainst
May 20, 2026Amazon.com, Inc.SHAREHOLDER PROPOSAL REQUESTING A REPORT ON CHARITABLE PARTNERSHIPS Shareholder proposalAgainstFor
May 20, 2026Amazon.com, Inc.SHAREHOLDER PROPOSAL REQUESTING ADDITIONAL REPORTING ON IMPACT OF DATA CENTERS ON CLIMATE COMMITMENTS Shareholder proposalForAgainst
June 5, 2026Alphabet Inc.Shareholder proposal regarding an enhanced disclosure on climate goals Shareholder proposalForAgainst
June 5, 2026Alphabet Inc.Shareholder proposal regarding a report on water usage and AI development Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

3,829 ballot items at 370 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Fidelity Growth Company Fund (FDGRX) voted at 370 shareholder meetings of 353 companies, on 3,829 ballot items in all. Where management made a recommendation, the fund followed it on 94.4% of the items and voted against it 205 times. Its most frequent area of disagreement was corporate governance (78 of its votes against management). It voted FOR 17.3% of the 214 shareholder proposals on which it cast a FOR or AGAINST vote. It voted FOR the board's own proposals less often than Fidelity's funds as a whole (92.6% against 94.1%). It voted differently from most Fidelity funds on 74 items. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Fidelity’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.